Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CTSO logo CTSO
Upturn stock ratingUpturn stock rating
CTSO logo

Cytosorbents Crp (CTSO)

Upturn stock ratingUpturn stock rating
$0.94
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: CTSO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $5

1 Year Target Price $5

Analysts Price Target For last 52 week
$5 Target price
52w Low $0.71
Current$0.94
52w High $1.61

Analysis of Past Performance

Type Stock
Historic Profit -48.02%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 59.21M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 2
Beta 1.2
52 Weeks Range 0.71 - 1.61
Updated Date 08/29/2025
52 Weeks Range 0.71 - 1.61
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.18

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.04
Actual -0.05

Profitability

Profit Margin -27.32%
Operating Margin (TTM) -37.59%

Management Effectiveness

Return on Assets (TTM) -20.1%
Return on Equity (TTM) -69.67%

Valuation

Trailing PE -
Forward PE 7.73
Enterprise Value 75566668
Price to Sales(TTM) 1.64
Enterprise Value 75566668
Price to Sales(TTM) 1.64
Enterprise Value to Revenue 2.09
Enterprise Value to EBITDA -1.92
Shares Outstanding 62761800
Shares Floating 54981852
Shares Outstanding 62761800
Shares Floating 54981852
Percent Insiders 15.46
Percent Institutions 26.66

ai summary icon Upturn AI SWOT

Cytosorbents Crp

stock logo

Company Overview

overview logo History and Background

CytoSorbents Corporation was founded in 1997 and is a critical care immunotherapy company focused on developing and commercializing blood purification technologies to treat life-threatening illnesses. Its main product is CytoSorb, an extracorporeal cytokine adsorber.

business area logo Core Business Areas

  • Critical Care: Develops and commercializes blood purification therapies for life-threatening conditions in the intensive care unit.
  • Cardiac Surgery: Applies CytoSorb technology to improve outcomes in cardiac surgery by reducing inflammation.
  • Transplantation: Investigates the use of CytoSorb in transplantation to reduce rejection risk.

leadership logo Leadership and Structure

The company is led by Phillip Chan, MD, PhD (Chief Executive Officer), and has a structure typical of a publicly traded company with a board of directors and various departments.

Top Products and Market Share

overview logo Key Offerings

  • CytoSorb: CytoSorb is the company's main product, designed to reduce excessive inflammation (cytokine storm) in critically ill patients. The product is approved in the European Union, but not yet approved in the United States. It's difficult to ascertain exact market share but it is significant within its applicable European market, especially for conditions like sepsis and during outbreaks of inflammatory illnesses. Competitors include companies developing similar blood purification technologies, and traditional therapies targeting inflammation, such as steroids. CytoSorbents also provides its HemoDefend and VetResQ product for targeted applications.

Market Dynamics

industry overview logo Industry Overview

The critical care and blood purification market is driven by the increasing prevalence of sepsis, acute respiratory distress syndrome (ARDS), and other inflammatory conditions. The market is competitive with various established and emerging technologies.

Positioning

CytoSorbents positions itself as a leader in cytokine adsorption, offering a unique solution for managing excessive inflammation in critical care settings. Its competitive advantage lies in the specific targeting of cytokines and its ability to be used in conjunction with other therapies.

Total Addressable Market (TAM)

The total addressable market for cytokine adsorption and blood purification therapies is estimated to be in the billions of dollars globally. CytoSorbents is positioned to capture a significant share of this market, particularly as it expands its regulatory approvals and clinical applications.

Upturn SWOT Analysis

Strengths

  • Proprietary CytoSorb technology
  • Approved in the European Union
  • Expanding clinical applications
  • Strong scientific evidence supporting efficacy

Weaknesses

  • Not yet approved in the United States
  • Reliance on single key product
  • Financial losses and need for financing
  • Dependence on reimbursement for adoption

Opportunities

  • FDA approval in the United States
  • Expansion into new clinical indications
  • Strategic partnerships
  • Growing awareness of cytokine storm

Threats

  • Competition from established and emerging therapies
  • Regulatory hurdles
  • Reimbursement challenges
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • BAX
  • NXTM

Competitive Landscape

CytoSorbents has a unique technology, but faces competition from larger, more established companies in the critical care and blood purification markets.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been characterized by periods of rapid expansion followed by slower progress, influenced by regulatory approvals and clinical trial outcomes.

Future Projections: Future growth depends heavily on FDA approval and expansion into new clinical indications. Analyst estimates vary, but generally project continued revenue growth with a path towards profitability.

Recent Initiatives: Recent initiatives include pursuing FDA approval for CytoSorb, expanding clinical trials into new indications, and seeking strategic partnerships.

Summary

CytoSorbents is a company with promising technology in the cytokine adsorption space but is facing significant challenges in achieving profitability and securing FDA approval. Its strengths lie in its proprietary technology and expanding clinical applications, but weaknesses include its lack of US approval and reliance on a single key product. Future success hinges on navigating regulatory hurdles, securing reimbursement, and expanding its market reach.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Analyst reports
  • Industry publications
  • Company website

Disclaimers:

The data provided is for informational purposes only and should not be construed as investment advice. Market share data are estimates and may not be precise. Always conduct thorough due diligence before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cytosorbents Crp

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 2013-11-07
CEO & Director Dr. Phillip P. Chan M.D., Ph.D.
Sector Healthcare
Industry Medical Devices
Full time employees 149
Full time employees 149

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.